Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Frontiers in Cardiovascular MedicineOpen Access

Preventing premature cardiovascular mortality: the role of lifestyle interventions and pharmacotherapy—a narrative review

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMarc HaberMNMichael NasrHEHadi Al Etri

Discussion

Loading...

Member takes

Overview

Narrative review highlights lifestyle interventions and pharmacotherapy to reduce cardiovascular diseases and mortality.

Key Points

  • Lifestyle interventions and pharmacotherapy significantly reduce risk of cardiovascular diseases.
  • Effective prevention strategies include physical activity, healthy diets like Mediterranean and DASH, and smoking cessation.
  • Pharmacotherapy with agents like aspirin and antihypertensive drugs lowers recurrent cardiovascular events in high-risk patients.
  • Emphasizes the need for precision medicine and artificial intelligence to enhance risk stratification and intervention efficacy.

Cite This Study

Haber et al. (2025) studied this question.

synapsesocial.com/papers/69401f0f2d562116f28fa15chttps://doi.org/10.3389/fcvm.2025.1664802
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association2021 · 3,727 citations
  2. 2Disparities in Cardiovascular Research Output and Disease Outcomes among High-, Middle- and Low-Income Countries – An Analysis of Global Cardiovascular Publications over the Last Decade (2008–2017)2021 · 72 citations
  3. 3Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2010 · 1,219 citations
  4. 4Association of dietary fiber intake with all-cause and cardiovascular mortality in U.S. adults with metabolic syndrome: NHANES 1999–20182025 · 6 citations
  5. 5Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials2024 · 144 citations